Aerocrine wins approval to market asthma test in China

Aerocrine’s method of measuring airway inflammation, using exhaled nitric oxide (NO) tests, has also been incorporated into China’s national guidelines for asthma management.

The new guidelines have resulted in a reimbursement code being designated for Aerocrine’s method to measure airway inflammation. The code is said to be the first big step towards doctors using Niox Mino securing payments per test.

In December 2007, Niox, Aerocrine’s larger device, was registered by the SFDA, the Chinese equivalent of the FDA. Clearance of Niox Mino allows the company’s Chinese partner Bioson to begin product sales for broad clinical use by Chinese physicians.